NCT03963362View on ClinicalTrials.gov

The Pharmacokinetics of GLA5PR Tablet According to the Renal Function

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

June 30, 2021

Conditions
Neuropathic Pain
Interventions
DRUG

GLA5PR tablet 75 mg

GLARS-NF3 tablet

DRUG

GLA5PR tablet 150 mg

GLARS-NF3 tablet

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

GL Pharm Tech Corporation

INDUSTRY

NCT03963362 - The Pharmacokinetics of GLA5PR Tablet According to the Renal Function | Biotech Hunter | Biotech Hunter